ScreenerHero

PCRX Pacira BioSciences, Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · pacira.com
25.05USD-0.63%Mkt Cap: 985.67M $P/E: 71.57

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The co…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$64.30BUSDP/E 25.0
TAK
Takeda Pharmaceutical Company Limited
$56.90BUSD
TEVA
Teva Pharmaceutical Industries Limited
$46.26BUSDP/E 66.1
HLN
Haleon plc
$38.79BUSDP/E 18.0
ZTS
Zoetis Inc.
$29.51BUSDP/E 11.7
ZOE
Zoetis Inc.
$28.27BUSDP/E 12.1
UTHR
United Therapeutics Corporation
$23.01BUSDP/E 19.2
VTRS
Viatris Inc.
$20.24BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.14BUSDP/E 110.6
NBIX
Neurocrine Biosciences, Inc.
$14.66BUSDP/E 21.1
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated
$11.25BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.26BUSDP/E 28.0
KRK
Krka, d. d.
$8.59BUSDP/E 19.2
ALKS
Alkermes plc
$7.17BUSDP/E 112.5
AMRX
Amneal Pharmaceuticals, Inc.
$7.09BUSDP/E 41.5
HIMS
Hims & Hers Health, Inc.
$6.92BUSD
LNTH
Lantheus Holdings, Inc.
$6.54BUSDP/E 24.3
KNSA
Kiniksa Pharmaceuticals International, plc
$5.87BUSDP/E 77.1
APTX
Apotex Health Corp.
$5.17BUSD

Key Statistics

Company
Market Cap985.67M USD
Enterprise Value1.17B USD
Revenue (TTM)746.16M USD
Gross Profit576.66M USD
Net Income (TTM)7.03M USD
Revenue/Share17.93 USD
Last Price25.05 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees825
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)71.57
P/E (Forward)7.32
PEG0.68
EV/EBITDA9.41
EV/Revenue1.56
P/S1.33
P/B1.49
EPS (TTM)0.35
EPS (Forward)3.44
52W Range
18.8071% of range27.66
52W High27.66 USD
52W Low18.80 USD
Profitability
Gross Margin79.39%
Oper. Margin6.17%
EBITDA Margin16.61%
Profit Margin0.97%
ROE1.01%
ROA0.56%
Growth
Revenue Growth6.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF151.99M USD
CapEx (TTM)15.33M USD
FCF Margin13.18%
FCF Yield9.98%
Net Debt161.09M USD
Net Debt/EBITDA1.30
Balance Sheet
Debt/Equity0.60
Current Ratio5.04
Quick Ratio3.21
Book Value/Sh16.87 USD
Cash/Share6.30 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.1 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)30.00 USD
Upside (mean)+19.8%
Target Range23.00 USD – 38.00 USD
23.00+19.8% to mean38.00
# Analysts9
Ownership
Shares Out.39.35M
Float36.19M
Insiders1.74%
Institutions113.30%
Short Interest
Short Ratio14.8d
Short % Float27.27%
Short % Out.18.97%
Shares Short7.56M
Short (prev mo.)7.30M
Technical
SMA 5025.26 (-0.8%)
SMA 20023.90 (+4.8%)
Beta0.27
S&P 52W Chg14.58%
Avg Vol (30d)513.60K
Avg Vol (10d)510.73K
Technical Indicators
RSI (14)48.2
MACD-0.0372
MACD Signal-0.0204
MACD Hist.-0.0168
BB Upper26.60 USD
BB Middle25.37 USD
BB Lower24.14 USD
BB Width9.69%
ATR (14)0.8066 USD
Vol Ratio (20d)1.07x